UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
X QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended July 3, 2005
OR
TRANSITION REPORT
PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition
period from________to_______
COMMISSION FILE
NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State of Incorporation)
13-5315170
(I.R.S. Employer Identification No.)
235 East 42nd
Street, New York, New York 10017
(212) 573-2323
(Registrant's telephone number)
Indicate by check mark whether the registrant (1) has
filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports) and (2)
has been subject to such filing requirements for the past 90 days.
YES X
NO
Indicate by check mark whether the registrant is an
accelerated filer (as defined in Rule 12b-2 of the Exchange Act).
YES X
NO
At August 1, 2005, 7,370,501,376 shares of the
issuer's voting common stock were outstanding.
FORM 10-Q
For the Quarter
Ended
July 3, 2005
Table
of Contents
PART I. FINANCIAL
INFORMATION
Page
Item 1.
Financial Statements:
Condensed
Consolidated Statement of Income for the three months and six months ended July 3,
2005 and June 27, 2004
Condensed
Consolidated Balance Sheet at July 3, 2005 and
December 31, 2004
Condensed
Consolidated Statement of Cash Flows for the six months ended July 3,
2005 and June 27, 2004
Notes to
Condensed Consolidated Financial Statements
Review Report
of Independent Registered Public Accounting Firm
17
Item 2.
Management's
Discussion and Analysis of Financial Condition and Results of Operations
18
Item 4.
Controls and
Procedures
42
PART II. OTHER INFORMATION
Item 1.
Legal
Proceedings
42
Item 2.
Unregistered
Sales of Equity Securities and Use of Proceeds
44
Item 6.
Exhibits
44
Signature
45
PART
I. FINANCIAL INFORMATION
Item 1. Financial Statements.
PFIZER INC AND
SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENT OF INCOME
(UNAUDITED)
Three Months Ended
Six Months Ended
(millions
of dollars, except per common share data)
July 3,
2005
June 27,
2004
July 3,
2005
June 27,
2004
Revenues
12,425
12,274
25,516
24,762
Costs
and expenses:
Cost of sales(a)
2,081
1,752
4,272
3,546
Selling, informational and administrative expenses(a)
4,226
4,258
8,311
8,191
Research and development expenses(a)
1,875
1,819
3,639
3,469
Amortization of intangible assets(a)
859
830
1,741
1,653
Merger-related in-process research and development
charges
260
--
262
955
Restructuring charges and merger-related costs
270
289
489
536
Other (income)/deductions - net
(207)
(102)
831
(145)
Income from continuing operations before (benefit)/provision
for taxes on income, and minority interests
3,061
3,428
5,971
6,557
(Benefit)/provision for taxes on income
(413)
582
2,222
1,390
Minority interests
Income from continuing operations
3,472
2,844
3,744
5,163
Discontinued operations:
(Loss)/income from discontinued operations - net
of tax
(9)
17
(22)
30
Gains on sales of discontinued operations - net
of tax
--
41
Discontinued operations - net of tax
(9)
19
19
32
Net income
3,463
2,863
3,763
5,195
Earnings
per common share - Basic:
Income from continuing operations
.47
.38
.51
.69
Discontinued operations - net of tax
--
--
--
--
Net income
.47
.38
.51
.69
Earnings
per common share - Diluted:
Income from continuing operations
.47
.38
.51
.68
Discontinued operations - net of tax
--
--
--
--
Net income
.47
.38
.51
.68
Weighted-average shares used to calculate earnings per
common share:
Basic
7,366
7,574
7,391
7,580
Diluted
7,418
7,664
7,445
7,672
Cash
dividends paid per common share
.19
.17
.38
.34
(a)
Includes
amortization of intangible assets, as disclosed in Note 9B,
Goodwill
and Other Intangible Assets: Other Intangible Assets.
See accompanying
Notes to Condensed Consolidated Financial Statements.
PFIZER INC AND SUBSIDIARY
COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEET
(UNAUDITED)
(millions
of dollars)
July 3,
2005*
Dec. 31,
2004**
ASSETS
Current Assets
Cash and cash
equivalents
1,276
1,808
Short-term
investments
13,293
18,085
Accounts
receivable, less allowance for doubtful accounts: 2005 - $220;
2004 - $205
9,316
9,367
Short-term
loans
513
653
Inventories
6,480
6,660
Prepaid
expenses and taxes
2,506
2,939
Assets held for
sale
189
182
Total current assets
33,573
39,694
Long-term
investments and loans
3,247
3,873
Property, plant
and equipment, less accumulated depreciation:
2005 - $8,982; 2004 - $8,534
17,673
18,385
Goodwill
23,627
23,756
Identifiable
intangible assets, less accumulated amortization
29,782
33,251
Other assets,
deferred taxes and deferred charges
4,425
4,725
Total assets
112,327
123,684
LIABILITIES
AND SHAREHOLDERS' EQUITY
Current Liabilities
Short-term
borrowings, including current portion of long-term debt:
2005 - $2,405; 2004 - $907
7,261
11,266
Accounts
payable
2,100
2,672
Dividends payable
1,406
1,418
Income taxes
payable
4,356
1,963
Accrued
compensation and related items
1,469
1,939
Other current
liabilities
5,934
7,136
Liabilities
held for sale
40
64
Total current liabilities
22,566
26,458
Long-term debt
5,517
7,279
Pension benefit
obligations
2,852
2,821
Postretirement
benefit obligations
1,444
1,450
Deferred taxes
on income
11,479
12,632
Other
noncurrent liabilities
3,141
4,766
Total liabilities
46,999
55,406
Shareholders' Equity
Preferred stock
180
193
Common stock
439
438
Additional
paid-in capital
67,426
67,098
Employee
benefit trust, at fair value
(1,052)
(1,229)
Treasury stock
(39,272)
(35,992)
Retained
earnings
36,446
35,492
Accumulated
other comprehensive income
1,161
2,278
Total shareholders' equity
65,328
68,278
Total liabilities and shareholders'
equity
112,327
123,684
* Unaudited.
** Condensed from audited
financial statements.
See accompanying
Notes to Condensed Consolidated Financial Statements.
PFIZER INC AND
SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(UNAUDITED)
Six Months Ended
(millions
of dollars)
July 3,
2005
June 27,
2004
Operating Activities:
Net income
3,763
5,195
Adjustments to reconcile net income to net cash
provided by continuing operating activities:
Discontinued operations - net of tax
(19)
(32)
Depreciation and amortization
2,776
2,517
Merger-related in-process research and development
charges
262
955
Asset impairment charge and other costs associated
with the suspension of Bextra sales
1,213
--
Deferred taxes
(127)
(222)
Other
49
463
Changes in assets and liabilities (net of businesses
acquired and divested)
(934)
(3,702)
Net
cash provided by continuing operating activities
6,983
5,174
Investing
Activities:
Purchases of property, plant and equipment
(997)
(961)
Purchases of short-term investments
(7,441)
(8,655)
Proceeds from redemptions of short-term investments
12,570
3,242
Purchases of long-term investments
(560)
(712)
Proceeds from sales of long-term investments
568
1,429
Purchases of other assets
(99)
(411)
Proceeds from sales of other assets
225
Acquisition of businesses, net of cash acquired
(255)
(1,443)
Proceeds from the sales of businesses and product
lines
101
575
Other investing activities
276
(59)
Net
cash provided by/(used in) investing activities
4,169
(6,770)
Financing
Activities:
Increase in short-term borrowings, net
90
3,360
Principal payments on short-term borrowings
(5,800)
(170)
Proceeds from issuances of long-term debt
1,588
Principal payments on long-term debt
(22)
(11)
Proceeds from common stock issuances
33
37
Purchases of common stock
(3,304)
(2,275)
Cash dividends paid
(2,930)
(2,562)
Stock option transactions and other
245
749
Net cash (used in)/provided by financing activities
(11,686)
716
Effect of exchange-rate changes on cash and cash
equivalents
12
Net decrease in cash and cash equivalents
(532)
(868)
Cash and cash equivalents at beginning of period
1,808
1,520
Cash and cash equivalents at end of period
1,276
652
Supplemental Cash Flow Information:
Cash paid during the period for:
Income taxes
1,296
1,853
Interest
329
194
Non-cash transaction:
Receivable from sale of business (received on
June 28, 2004)
--
450
See accompanying
Notes to Condensed Consolidated Financial Statements.
PFIZER
INC AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1: Basis of Presentation
General
We prepared the condensed consolidated financial statements
following the requirements of the Securities and Exchange Commission (SEC) for
interim reporting. As permitted under those rules, certain footnotes or other
financial information that are normally required by accounting principles
generally accepted in the United States of America (GAAP) can be condensed or
omitted. Balance sheet amounts and operating results for subsidiaries operating
outside the U.S. are as of and for the three-month and six-month periods ended May 29,
2005 and May 23, 2004. The fiscal first quarter and six months of 2005 had
three additional business days compared to the fiscal first quarter and six
months of 2004.
We made certain reclassifications to the 2004 condensed
consolidated financial statements to conform to the 2005 presentation.
Revenues, expenses, assets and liabilities can vary during
each quarter of the year. Therefore, the results and trends in these interim
financial statements may not be representative of those for the full year.
We are responsible for the unaudited financial statements
included in this document. The financial statements include all normal and
recurring adjustments that are considered necessary for the fair presentation
of our financial position and operating results.
The information included in this Quarterly Report on
Form 10-Q should be read in conjunction with the consolidated financial
statements and accompanying notes included in Pfizer's Annual Report on
Form 10-K for the year ended December 31, 2004.
Share-Based Payments
In accordance with Statement of Financial Accounting
Standards (SFAS) No. 123, Accounting for Stock-Based Compensation, we
elect to account for our stock-based compensation under Accounting Principles
Board Opinion No. 25, Accounting for Stock Issued to Employees. The
exercise price of stock options granted equals the market price on the date of
grant; therefore, there is no recorded compensation expense related to grants
of stock options.
The weighted-average fair value
per stock option granted was $3.23 and $4.49 for the three months ended July 3,
2005 and June 27, 2004 and $5.15 and $6.88 for the six months ended
July 3, 2005 and June 27, 2004. We estimated the fair values, as
required under GAAP, using the Black-Scholes option-pricing model, modified for
dividends and using the assumptions below. Pro forma compensation expense
related to stock options subject to accelerated vesting upon retirement is
recognized over the period of employment up to the vesting date of the grant.
In the first quarter of 2005, we changed our method of estimating expected
dividend yield from historical patterns of dividend payments to a method that
reflects a constant dividend yield during the expected term of the option.
Three Months Ended
Six Months Ended
July 3,
2005
June 27,
2004
July 3,
2005
June 27,
2004
Expected dividend yield
2.72%
2.57%
2.90%
2.90%
Risk-free interest rate
3.75%
2.07%
3.96%
3.32%
Expected stock price volatility
16.90%
20.43%
21.93%
22.15%
Expected term until exercise
(years)
2.75
3.26
5.75
5.75
The following table shows the
effect on results for the three-month and six-month periods ended July 3,
2005 and June 27, 2004 if we had applied the fair-value-based recognition
provisions of SFAS 123 to measure stock-based compensation expense for the
option grants:
Three
Months Ended
Six
Months Ended
(millions
of dollars, except per common share data)
July 3,
2005
June 27,
2004
July 3,
2005
June 27,
2004
Net income
available to common shareholders used in the calculation of basic earnings
per common share:
As reported
under GAAP*
3,461
2,862
3,761
5,193
Compensation
expense - net of tax
(104)
(147)
(252)
(273)
Pro forma
3,357
2,715
3,509
4,920
Basic earnings
per common share:
As reported
under GAAP*
.47
.38
.51
.69
Compensation
expense - net of tax
(.01)
(.02)
(.04)
(.04)
Pro forma
.46
.36
.47
.65
Net income
available to common shareholders used in the calculation of diluted earnings
per common share:
As reported
under GAAP*
3,461
2,862
3,761
5,192
Compensation
expense - net of tax
(104)
(147)
(252)
(273)
Pro forma
3,357
2,715
3,509
4,919
Diluted
earnings per common share:
As reported
under GAAP*
.47
.38
.51
.68
Compensation
expense - net of tax
(.02)
(.02)
(.04)
(.04)
Pro forma
.45
.36
.47
.64
Includes
stock-based compensation expense, net of related tax benefits, of $53 million
for the six months ended July 3, 2005 ($38 million for the three
months ended July 3, 2005) and $40 million for the six months ended
June 27, 2004 ($10 million for the three months ended June 27,
2004).
Net income available to common shareholders used in the
calculation of basic earnings per common share represents net income reduced by
preferred stock dividends - net of tax. Net income available to
common shareholders used in the calculation of diluted earnings per common share
represents net income reduced by the incremental allocation of shares to the
Employee Stock Ownership Plans (ESOPs) acquired as part of the Pharmacia
acquisition.
Note 2: Asset Impairment Charge and Other
Costs Associated with the Suspension of Bextra Sales
In the first six months of 2005, we recorded charges
totaling $1.2 billion ($761 million, net of tax) in connection with the
decision to suspend sales and marketing of Bextra. This decision resulted from
an April 7, 2005 request from the U.S. Food and Drug Administration (FDA),
as part of its safety review of all COX-2 medicines.
The pre-tax charges included
$1.1 billion related to the impairment of developed technology rights
associated with Bextra and $7 million related to the write-off of
machinery and equipment, both of which are included in Other
(income)/deductions - net. In addition, in connection with the
suspension, we also recorded $56 million in write-offs of inventory and
exit costs, included in Cost of sales; $5 million related to the
costs of administering the suspension of sales, included in Selling,
informational and administrative expenses; and $173 million, for an
estimate of customer returns, primarily included against Revenues.
Substantially all of these charges were recorded in the first quarter of 2005.
Note 3: Income Taxes
Income Tax Charge Associated with Repatriation Decision
In the first six months of 2005, we recorded an income tax
charge of $1.7 billion, included in (Benefit)/provision for
taxes on income, in connection with our decision to repatriate about $36.7 billion
of foreign earnings in accordance with the American Jobs Creation Act of
2004 (the Jobs Act). In the first quarter of 2005, we recorded an initial
estimated income tax charge of $2.2 billion based on the decision to
repatriate $28.3 billion of foreign earnings; in the second quarter of
2005, we reduced our original estimate of the tax charge by $863 million
and revised the repatriation of foreign earnings to $28.1 billion,
principally as a result of guidance issued by the U.S. Treasury in May 2005. In
the second quarter of 2005, we also recorded an additional tax charge of $373 million,
primarily due to our decision to repatriate an additional $8.6 billion of
foreign earnings.
As of July 3, 2005, we intend to continue to reinvest
the earnings of our international subsidiaries and, therefore, we have not
recorded a U.S. tax provision on the remaining amount of unremitted earnings.
Tax Contingencies
In the second quarter of 2005, we recorded a tax benefit of
$586 million primarily related to the resolution of certain tax positions.
We believe that the IRS audits of the Pfizer Inc. tax returns for the years
1999-2001 and the Warner-Lambert Company tax returns for the years 1999 through
the date of the merger with Pfizer (June 19, 2000) are substantially
complete. In connection with those audits, we are currently in the process of
appealing one matter related to the tax deductibility of a breakup fee paid by
Warner-Lambert Company in 2000.
The IRS has commenced the audit of the Pfizer Inc. tax returns
for the years 2002 and 2003. The 2005 tax year is also currently under audit.
As previously disclosed, with respect to Pharmacia
Corporation (formerly known as Monsanto Company), the IRS has completed and
closed its income tax return examinations and appeals through 1999 and has
commenced the audit of the tax returns for the years 2000 through the date of
merger with Pfizer (April 16, 2003).
We periodically reassess the likelihood of assessments
resulting from audits of federal, state and foreign income tax filings. We
believe that our accruals for tax liabilities are adequate for all open years.
Note 4: Adapting to Scale Initiative
We recently launched a company-wide initiative, called
Adapting to Scale (AtS), which involves a comprehensive review of our
processes, organizations, systems and decision making. In the second quarter of
2005, in connection with this AtS initiative, we incurred and paid approximately
$21 million in restructuring charges, primarily related to employee
termination costs at our manufacturing facilities located in North America. We
also incurred and paid approximately $33 million in implementation costs,
included in Cost of sales ($1 million), Selling, informational
and administrative expenses ($21 million) and Research and
development expenses ($11 million), primarily related to system and
process standardization and the expansion of shared services.
We now expect the costs associated with this multi-year
effort to continue through 2008 and to total approximately $4 billion to